1339058-04-6
基本信息
1-((4-羥基-1-(苯基甲基)-4-哌啶基)甲基)-2(1H)-吡啶酮鹽酸鹽
CS-2407
YL0919 (YL-0919
YL0919 hydrochloride
報價日期 | 產(chǎn)品編號 | 產(chǎn)品名稱 | CAS號 | 包裝 | 價格 |
2024/11/08 | HY-100769 | CS-2407 Hypidone hydrochloride | 1339058-04-6 | 2 mg | 500元 |
2024/11/08 | HY-100769 | CS-2407 Hypidone hydrochloride | 1339058-04-6 | 5 mg | 800元 |
2024/11/08 | HY-100769 | CS-2407 Hypidone hydrochloride | 1339058-04-6 | 10 mM * 1 mLin DMSO | 921元 |
常見問題列表
5-HT 1A Receptor
|
YL0919 inhibits the uptake of [ 3 H]-5-HT into rat cerebral cortical synaptosomes and HEK293 cells stably expressing hSERT with IC 50 values of 1.78 nM and 1.93,respectively.YL0919 (0.01 nM-10 μM) concentration-dependently inhibits forskolin-stimulated cAMP formation,? exerts a concentration-dependent inhibitory effect on cAMP formation with an IC 50 of approximately 23.9 nM. And in antagonism studies, WAY-100635?prevents YL0919-mediated inhibition of forskolin-stimulated cAMP formation. YL0919 shows affinities to rat 5-HT1A?receptors, SERTs, NETs, and DATs, it binds to 5-HT1A?receptor, serotonin transporter (SERT) with high affinity (K i =0.19 and 0.72 nM, respectively), but its affinity to NET and DAT are low, blocking [ 3 H]nisoxetine and [ 3 H]win35428 binding with Ki?values of 650 nM and 2652 nM respectively.
YL0919 (oral administration; 1.25 or 5 mg/kg; 4 weeks) and fluoxetine (10 mg/kg) reverses the inhibition of locomotor activity in CUS rats.YL0919 (oral administration; 1.25, 2.5, and 5 mg/kg; 4 weeks) significantly reduces the immobility time in TST in mcie FST in mice. Besides, YL0919 displays no effect on the locomotor activity in a separate OFT. Furthermore, the antidepressant-like effect of YL0919 in TST and FST is completely bunted by coadministration with WAY-100635.
Animal Model: | Male ICR mice weighing 18–22 g |
Dosage: | 1.25, 2.5, and 5 mg/kg |
Administration: | Oral administration |
Result: | Had an effect on Antidepressant-like mice in TST and FST. |